Our data suggest that abrogation of GH signaling in liver results in a metabolic profile consistent with that observed in the human metabolic syndrome, hepatic steatosis (NAFLD), which may progress to hepatic fibrosis, inflammation (NASH), and liver dysfunction (increased ALT/AST) eventually leading to hepatic adenoma formation. The gene discussed is GPT; the disease is Hepatic fibrosis.